SNDX SYNDAX PHARMACEUTICALS INC Other Situations 8-K Filing 2023 - Updates on Clinical Programs Syndax Pharmaceuticals provided updates on their clinical programs, including positive data from trials for axatilimab and revumenib, in press releases and an investor event at the ASH Annual Meeting.Get access to all SEC 8-K filings of the SYNDAX PHARMACEUTICALS INC